Oncologist & researcher at Università del Piemonte Orientale Marie-Curie PhD fellow
Novara, Italy
Joined October 2018
- Tweets414
- Following395
- Followers699
- Likes794
Benedetta Conte retweeted
La dott.ssa @BenedettaConte5, oncologa e docente @UniAvogadro, ha ottenuto un finanziamento @AIRC_it per il progetto NEOMET
Lo studio valuterà omega-3 e attività fisica sull’efficacia delle terapie nel tumore al seno
Complimenti a Benedetta e al team della Prof.ssa @ALEDIGNUS12
Out in #ClinicalCancerResearch the results of the TATEN trial in HR+/HER2- mBC post-CDK4/6i.
Non-luminal, highly proliferative, immune-enriched tumors showed >24m PFS with pembrolizumab maintenance. Article here: lnkd.in/eYASVuaT
@SOLTI #cancerresearch
Che bella sensazione leggere il nome di @filippoconte94 come autore di un pezzo su @LaStampa !!!
lastampa.it/politica/2024/08…
7
379
Super @fara_bm and colleagues!!!!
This Post is from an account that no longer exists. Learn more
7
435
Benedetta Conte retweeted
Hi from Vienna!
If you are in the city, join us tomorrow at @IMPvienna for the "Metastasis mechanisms workshop" with @johannes_zuber @JulianeScience @MomoBentires and @BMaierLab
📢The Evomet network will meet soon in Vienna for the 4th Annual meeting, hosted by @IMPvienna and @Boehringer
👉If you are in Vienna, join us for the "Metastasis mechanisms workshop"! Amazing speakers lined-up! 🗣️
@johannes_zuber @JulianeScience @MomoBentires @BMaierLab
Benedetta Conte retweeted
I never imagined how fulfilling this would be. Thrilled to announce that our #DEFINITIVEtrial now has an NCT number: NCT06446882.
First SIV this summer!
🔗Link clinicaltrials.gov/study/NCT…
Benedetta Conte retweeted
Great discussion by dr Krop @Yale: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24
@OncoAlert
Benedetta Conte retweeted
At #ASCO24 @matteolambe presents analysis on BRCA BCY Collaboration including young BRCA carriers affected by eBC:
➡️ Different clinical behavior between BRCA1 and 2 carriers
➡️ Early identification of carriers can lead to improvement in prognosis
@OncoAlert @UniGenova
Benedetta Conte retweeted
Patient-level meta-analysis shows HER2DX is associated with survival outcomes in patients with early-stage HER2+ BC presented by @G_Villacampa
#ESMOBreast24 @OncoAlert #bcsm
Benedetta Conte retweeted
#ESMOBreast24 key takeaways
@lab_kok Wishlist includes #HER2DX and the development of thedefinitivetrial.eu to achieve better outcomes
#precisiononcology
#breastcancer
Super importante conference! Do not miss it!! ⬇️⬇️⬇️⬇️⬇️
This Post is from an account that no longer exists. Learn more
Benedetta Conte retweeted
Why was IMpassion132 negative? And what’s the path forward for improving outcomes in early recurrent TNBC? Great discussion by Sara Tolaney (@stolaney1), recapitulating the current status & future hopes for one of the most challenging presentations of breast cancer. #ESMOBreast24
Benedetta Conte retweeted
Proffered paper session 1 at #ESMOBreast24: first results from #DOLAF trial showing very promising activity in advanced ER+/HER2- #BreastCancer of the combination #olaparib #durvalumab and #fulvestrant particularity in #BRCA carriers
@myESMO #ESMOambassadors @OncoAlert #bcsm
Benedetta Conte retweeted
@CarmenCriscit approaching several controversies in the real world oncology in BRCA/HR+ adjuvant scenario
▪️How to choose between CDKi and PARPi?
▪️ Are CDKi less effective in BRCAmut?
▪️ Can we combine at least sequentially CDKi and PARPi?
#ESMOBreast24 #ESMOAmbassadors
Benedetta Conte retweeted
Just out 🚨on @eBioMedicine
Study explores the potential of a B-cell/immunoglobulin signature (IGG), alone or combined with tumor burden, to predict prognosis and treatment response in early-stage triple-negative #BreastCancer
➡️ indicating its promise in guiding personalized treatment decisions
thelancet.com/journals/ebiom…
@BenedettaConte5
@fara_bm
@AdelaRodrguezH1
@TomasPascualMD
@G_Villacampa
@FrancescoSche20
@OlgaMartnezSez1
@MVidalMD
@esther_sanfeliu
@ClaudetteFalato
@Nchic5
@AnaVivancosVHIO
@patri0608
@prat_aleix
Benedetta Conte retweeted
🎯 B-cell/immunoglobulin signature (IGG) was associated with improved EFS (HR = 0.77) and OS (HR = 0.79) across 7 cohorts of early stage TNBC
🕵🏼♀️IGG + clinical features could help identifying pts benefitting from intensified or de-intensified tp
👏🏻 🤩@BenedettaConte5
@OncoAlert
Editor pick from April issue
@BenedettaConte5 @prat_aleix @fara_bm & coll
Identified a 14-gene immunoglobulin B-cell signature linked to improved prognosis and pathological complete response in patients with early-stage triple-negative breast cancer
Read bit.ly/4b7WpYM
Very happy to see that our paper on @eBioMedicine is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️@prat_aleix @evomet_itn @fara_bm
Editor pick from April issue
@BenedettaConte5 @prat_aleix @fara_bm & coll
Identified a 14-gene immunoglobulin B-cell signature linked to improved prognosis and pathological complete response in patients with early-stage triple-negative breast cancer
Read bit.ly/4b7WpYM
Benedetta Conte retweeted
👇Check this new article from our own @BenedettaConte5 @prat_aleix and @fara_bm 👏👏👏
This Post is from an account that no longer exists. Learn more
Out our new article on @eBioMedicine exploring the role of B-cell immunity in TNBC.
🧵below
🗞️open access here: authors.elsevier.com/sd/arti…
@OncoAlert
Finally, we used CIBERSORTx and ECOtyper to assess the immune cells and ecosystems reflected by IGG. IGG-high tumors are enriched for plasma cells, CD8+, and follicular helper cells, and belong to ecotypes CE9-10, corresponding to the highest
levels of immunoreactivity
